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Abstract: Chronic opioid usage (COU) is common among patients with
end-stage renal disease (ESRD) qualiﬁed for kidney transplantation and
associated with inferior post-transplant outcomes. The magnitude of
COU after kidney transplantation and its impact on transplant outcomes
remain unknown. We performed a single-center retrospective study
aimed to describe the prevalence of COU during the ﬁrst year, to identify
the predictors of COU and to determine the impact of COU on post-
transplant outcomes including the rates of hospitalization and acute
rejection during the ﬁrst year, as well as long-term patient and graft
survival. Among 1045 kidney transplant patients, 119 (11.4%) had
required continued outpatient prescription of opioid analgesics during
the ﬁrst year after kidney transplantation, mostly for non-surgery-related
pain (85%). A positive history of COU prior to transplantation was the
strongest predictor of COU in the ﬁrst year post-transplantation
(adjusted odds ratio [AOR] 4.31, p < 0.001). Patients with COU had
more often hospital admission during the ﬁrst year (AOR 2.48,
p = 0.001, for 1 or 2 admissions, and AOR 6.03, p < 0.001 for ≥3
admissions), but similar rate of acute rejection (19.3% vs. 15.7%,
p = 0.31). During long-term follow-up, however, the patient and/or
death-censored kidney survival was not diﬀerent. COU early post-kidney
transplantation, when clinically indicated and properly supervised, does
not appear to aﬀect the risk of death and death-censored graft failure.
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Kidney transplantation is the treatment of choice
for a large majority of patients with end-stage renal
disease (ESRD) as it provides survival advantage
and improvement in the quality of life compared to
the dialysis therapy (1, 2). Patient and kidney graft
survival has improved over the years with the mod-
ern immunosuppression and dedicated patient
management (3). Consequently, the issues pertain-
ing to health-related quality of life are now attain-
ing more recognition. Chronic pain is one such
issue that is highly prevalent in the chronic dialysis
population and reported by nearly half of the
patients with ESRD undergoing maintenance dial-
ysis therapy (4, 5).
The management of chronic pain among
patients with ESRD is often inadequate. The
patients on dialysis are seen weekly but focus is pri-
marily on the adequacy of dialysis and factors
directly related to delivery of dialysis. Nephrolo-
gists are perceived to be reluctant in delving into
chronic pain problem and in prescribing nonsteroi-
dal anti-inﬂammatory drugs (NSAIDs) to these
patients (6, 7). Opioids are the alternative analge-
sics with up to 36% of dialysis patients being pre-
scribed opioid analgesics chronically in the USA
(7, 8). The use of opioid analgesics, both short term
and long term, is associated with a variety of
adverse eﬀects that are dose dependent and often
enhanced in the setting of renal failure (9–11). We
have recently observed that a history of chronic
opioid analgesic usage (COU) prior to kidney
transplantation was associated with inferior
patient survival post-transplantation (12).
There are few studies examining the presence of
chronic pain and the use of analgesics for the man-
agement of pain after kidney transplantation. One
recent observational study suggested no major dif-
ference in the point-prevalence of chronic pain
reported by ESRD patients on dialysis (63%) and
by stable kidney transplant patients (62%). In this
study, 15% of dialysis patients and 37% of kidney
transplant patients received no analgesics for their
pain relief (13). To date, there are no published
data on the magnitude of opioid analgesic usage
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after kidney transplantation and its potential
impact on the transplant outcomes. To ﬁll this
knowledge gap, we performed a single-center
observational study investigating the magnitude of
opioid analgesic usage during the ﬁrst year post-
transplantation and its impact on both the short-
and the long-term post-transplant outcomes.
Materials and methods
Study design and patient population
This is a single-center observational study that
included all adult patients who received a kidney
transplant between January 1, 2004 and December
31, 2008 with follow-up through December 31,
2012. Patients were excluded if they received simul-
taneous multi-organ transplants, died, or lost their
kidney transplant before three months. The period
of initial three months was chosen to allow for con-
siderable duration of opioid usage after transplan-
tation. This study was approved by the
institutional review board (IRB).
Demographic and baseline characteristics of the
study population as well as subsequent follow-up
information including the number of hospital
admission and biopsy-documented acute rejection
during the ﬁrst year, patient and kidney graft sur-
vival were obtained from the institutional elec-
tronic medical record database. A history of
chronic pain and chronic opioid analgesics use
prior to kidney transplantation was ascertained at
the time of initial kidney transplantation
evaluation and during subsequent pre-transplant
follow-up as part of the evaluation process by a
multidisciplinary team composed of transplant
nephrologists, surgeons, and social workers. Addi-
tional baseline characteristics included a history of
past illicit drug abuse and psychiatric diagnosis
among others. However, none of the patients
reported active recreational drug abuse because
active drug abuse is an exclusion clause for kidney
transplantation in our center’s recipient selection
policy. Similarly, any patient with a positive psy-
chiatric history, which included mood disorders,
schizophrenia, and personality disorders would
have to have symptoms under stable control prior
to be considered as a suitable candidate to receive
kidney transplantation.
Assessment of chronic opioid usage and pain first
year post-transplantation
We determined the active use of opioid analgesics
by documenting the presence of opioid analgesic
prescription in the outpatient setting, associated
with the complaint of pain, at three time intervals:
four to eight wk, three to six months, and 10–
12 months after transplantation through detailed
review of institutional electronic medical records.
The standard deﬁnition of opioid analgesics was
used (14). Chronic opioid usage (COU) was
deﬁned as active use of opioid analgesics at all the
three time intervals or ﬁrst two time intervals if the
patient had an event (death and/or graft loss)
between three and 12 months. Transient opioid
administration for acute events in an inpatient set-
ting was not counted. We also did not include the
opioid usage during the ﬁrst four wk, because all
our patients were prescribed as-needed opioid
analgesics upon the discharge from the initial hos-
pitalization and the prescription stays active in the
electronic chart for four wk. Eﬀort was made to
include only those who had unequivocal documen-
tation of continued opioid analgesic use.
The cause of pain was classiﬁed into four catego-
ries: iatrogenic, arthritis/degenerative joint disease,
neuropathic and others. The ﬁrst category com-
prised all pain descriptions suggesting location to
be site of the invasive procedure, namely pain in
the area with recent surgical intervention was clas-
siﬁed as iatrogenic. Any pain characterized to be
joint pain was classiﬁed as arthritis/degenerative
joint disease, documented neuropathic pain was
classiﬁed as such. All other cases were put into
“other” category.
Assessment of clinical correlates of COU and post-
transplant outcomes
We separated the study population into two
groups according to COU status (yes or no). We
assessed the potential association of various demo-
graphic and baseline characteristics with COU. We
compared the frequency of hospital readmission
(none, 1 or 2, 3 or more) and biopsy-documented
acute rejection during the ﬁrst year, the patient and
death-censored kidney graft survival during subse-
quent follow-up between the two groups.
Statistical analysis
Categorical variables were expressed as propor-
tions and compared using chi-square (v2) test.
Continuous variables were expressed as mean
 SD and compared using the Student’s t-test.
Logistic regression analyses were performed to
identify the predictors of COU and its association
with hospital admissions and acute rejection
during the ﬁrst year post-kidney transplantation.
Kaplan–Meier survival and Cox regression analy-
ses were performed to compare patient and/or
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death-censored kidney graft survival between the
groups with and without COU. All patient, donor,
and transplant characteristics were considered for
inclusion in the multivariate models. Final models
included those variables with p < 0.10 after back-
ward selection.
All statistical tests were two-sided, and a p value
equal to or <0.05 was considered signiﬁcant. Statis-




Among 1045 solitary kidney transplant patients
who met the inclusion criteria, everyone had an
active opioid prescription during the ﬁrst month
(center’s policy). During the second month, 261
patients (24.5%) had active opioid use, 176
patients (16.8%) between three and six months,
and 148 patients (14.6%) between 10 and
12 months post-transplantation, respectively, had
active opioid analgesic use. COU during the ﬁrst
year (Fig. 1) was noted in 119 of 1045 patients
(11.4%). Mean age of our recipients’ cohort was
49.3  13.2 yr with 62.8% (668) being males and
18.1% (193) being African Americans. The most
commonly prescribed opioid analgesic was hydro-
codone (59.4%) followed by oxycodone (29.8%),
hydromorphone (5.2%), fentanyl (2.9%), and oth-
ers (2.7%) (Fig. 2A). The most common cause of
pain for which the opioid analgesics were pre-
scribed was related to pre-existent arthritis (57%)
followed by neuropathic pain (19%), iatrogenic
pain (15%), and others (9%) (Fig. 2B).
The demographic and baseline characteristics
between patients with and without COU are shown
in Table 1. The patients from two groups were
comparable with regard to age, gender, BMI,
underlying diabetes mellitus, HCV sero-status, col-
lege education, proportion receiving ﬁrst kidney
transplant and PRA ≥ 20%. The COU patients
more frequently had a positive history of pre-trans-
plant chronic opioid usage (33.6% vs. 7.0%, p <
0.001), chronic pain (66.4% vs. 39.2%, p < 0.001),
psychiatric disorders (52.1% vs. 27.5%, p <
0.001), illicit drug usage (21.9% vs. 10.8%,
p = 0.001), and alcohol abuse (16.0% vs. 10.2%,
p = 0.05) prior to transplantation. The COU
patients were more often African American
(25.2% vs. 17.7%, p = 0.05) and a former or cur-
rent smoker (64.7% vs. 48.3%, p = 0.001), longer
dialysis vintage (3.2  3.3 vs. 2.3  2.6 yr,
p = 0.004), less likely to be employed (26.1% vs.
44.0%, p < 0.001), and to have private health
insurance (28.6% vs. 44.6%, p = 0.001). They
(COU) were less likely to receive a preemptive kid-
ney transplant (15.1% vs. 26.7%, p = 0.006) and a
living donor kidney transplant (35.3% vs. 52.3%,
p = 0.001). The COU patients received ECD
(20.2% vs. 12.2%, p = 0.02) and/or DCD kidney
(13.5% vs. 6.5%, p = 0.006) more often. Finally,
COU patients had longer initial hospital stay
(7.4  5.8 vs. 5.2  3.6 d, p < 0.001), experienced
more delayed graft function (27.2% vs. 12.9%,
p < 0.001), and received more frequently induction
with rabbit antithymocyte globulin (rATG)
(31.9% vs. 23.2%, p = 0.04).
Predictors of COU during the first year after
transplantation
As shown in Table 2, among all the demographic
and baseline characteristics, a history of pre-
transplant COU was the strongest predictor of
post-transplant COU (adjusted odds ratio [AOR]
4.31, 95% CI 2.60, 7.16, p < 0.001). Additional
predictors included a positive history of psychiatricFig. 1. Opioid use at various time-points.
A
B
Fig. 2. (A) Opioid usage pattern among the post-transplant
chronic opioid user. (B) Characteristics of pain in post-
transplant chronic opioid users.
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disorders (AOR 2.27; 95% CI 1.49, 3.45,
p < 0.001), chronic pain before transplantation
(AOR 2.04, 95% CI 1.30, 3.20, p = 0.002), illicit
drug abuse (AOR 1.98, 95% CI 1.14, 3.43,
p = 0.01), the use of induction therapy with rATG
(AOR 1.82, 95% CI 1.15, 2.88, p = 0.01), prior or
current smoking history (AOR 1.60, 95% CI 1.03,
2.47, p = 0.04), and length of initial inpatient stay
(days) (AOR 1.10, 95% CI 1.05, 1.14, p < 0.001).
COU and clinical outcomes
Hospitalizations. There were 1131 hospital admis-
sions documented during the ﬁrst year among 1045
patients: 518 with no admission, 384 with 1 or 2
admissions and 143 with 3 or more admissions,
respectively. There were more hospital admissions
among patients with COU than patient with no
COU (v2, p < 0.001) (Fig. 3). In fact, patients with
COU were twice more likely to have 1 or 2 admis-
sions (AOR 2.48, 95% CI 1.49, 4.13, p = 0.001)
and 6 times more likely to have multiple (≥3) admis-
sions (AOR 6.03, 95% CI 3.39, 10.75, p < 0.001)
during the ﬁrst year post-transplantation.
Acute rejection. There were 168 patients with
biopsy-documented acute rejection during the ﬁrst
year. There was no signiﬁcant diﬀerence in inci-
dence of acute rejection during the ﬁrst year
between patients with and without COU (19.3%
vs. 15.7%, v2, p = 0.31), as shown in Fig. 4.
Patient and graft survival. We investigated the
occurrence of death and/or death-censored kidney
graft failure in relation to COU. In univariate
analysis, patients with COU appeared to be at an
increased risk for death (HR 1.61, 95% CI 1.13,
2.32, p = 0.009) and death-censored kidney graft
failure (HR 1.96, 95% 1.23, 3.10, p = 0.004). How-
ever, after adjusting for multiple baseline and
demographic characteristics, as well as the





(n = 119) p
Recipient characteristics
Age, years (SD) 49.1 (13.4) 50.6 (12.0) 0.24
Gender, male, n (%) 584 (63.1) 72 (60.5) 0.59
African American, n (%) 164 (17.7) 30 (25.2) 0.05
BMI, kg/m2 (SD) 28.4 (5.6) 28.6 (6.4) 0.68
First transplant, n (%) 797 (86.1) 104 (87.4) 0.69
HCV-positive serology, n (%) 39 (4.2) 9 (7.6) 0.10
Preemptive transplant, n (%) 247 (26.7) 18 (15.1) <0.01
Dialysis duration, years (SD) 2.3 (2.6) 3.2 (3.3) <0.01
Employed, n (%) 407 (44.0) 31 (26.1) <0.01
Private health
insurance, n (%)
413 (44.6) 34 (28.6) 0.01
Diabetes mellitus, n (%) 312 (33.7) 47 (39.5) 0.21
Psychiatric history, n (%) 255 (27.5) 62 (52.1) <0.01
Positive smoking
history, n (%)
447 (48.3) 77 (64.7) <0.01
History of chronic
pain, yes (%)
363 (39.2) 79 (66.4) <0.01
COU prior to
transplantation, yes (%)
65 (7.0) 40 (33.6) <0.01
History of alcohol
abuse, n (%)
94 (10.2) 19 (16.0) 0.05
History of illicit drug use, n (%) 100 (10.8) 26 (21.9) <0.01
College education, n (%) 444 (48.0) 58 (48.7) 0.87
PRA ≥ 20%, n (%) 204 (22.0) 27 (22.7) 0.87
Donor characteristics
Age, years (SD) 39.7 (13.3) 38.2 (14.6) 0.22
Gender, male (%) 486 (52.5) 65 (54.6) 0.66
Living donor, n (%) 484 (52.3) 42 (35.3) <0.01
ECD, n (%) 113 (12.2) 24 (20.2) 0.02
DCD, n (%) 60 (6.5) 16 (13.5) <0.01
Transplant characteristics
CMV D+/R, n (%) 191 (20.6) 20 (16.8) 0.33
Cold ischemia time, hours (SD) 7.7 (6.8) 9.7 (6.9) <0.01
HLA mm, n (SD) 3.2 (1.9) 3.2 (1.9) 0.87
Initial hospital stay, days (SD) 5.2 (3.6) 7.4 (5.8) <0.01
CNIs, CsA, n (%) 846 (91.4) 113 (95.0) 0.18
Delayed graft function, n (%) 120 (13.0) 31 (26.1) <0.01
Induction with rATG, n (%) 215 (23.2) 38 (31.9) 0.04
COU, chronic opioid usage.
Table 2. Predictors of chronic opioid usage (COU) after transplanta-
tion
Variables AOR 95% CI p
COU prior to transplantation, yes 4.31 2.60, 7.16 <0.01
Positive psychiatric history, yes 2.27 1.49, 3.45 <0.01
Chronic pain prior to transplantation, yes 2.04 1.30, 3.20 <0.01
History of illicit drug use, yes 1.98 1.14, 3.43 0.01
Induction with rATG, yes 1.82 1.15, 2.88 0.01
Prior or current smoking habit, yes 1.60 1.03, 2.47 0.04
Length of initial inpatient stay, days 1.10 1.05, 1.14 <0.01




occurrence of acute rejection, baseline renal func-
tion and hospital admission, such association was
no longer statistically signiﬁcant. Results of multi-
variate Cox proportional hazards model for the
combined outcome of death and/or graft loss are
shown in Table 3. The tables 4 and 5 show the
results of multivariate analysis of individual out-
comes, death and death censored graft loss in the
ﬁrst year respectively.
Discussion
To the best of our knowledge, this is the ﬁrst cohort
study looking at post-transplant chronic opioid
usage and its consequences in kidney transplant
recipients. Our study adds to pre-existing knowl-
edge about this issue, which has come from small
cross-sectional studies that used one-time question-
naire data (4, 13). Our study showed that continued
requirement for opioid prescription during the ﬁrst
year post-transplantation was common, observed
in about 11% of patients among our cohort.
Although we observed a positive association
between COU and hospitalization during the ﬁrst
year post-transplantation, the long-term transplant
outcomes and patient and death-censored kidney
graft survival were similar among patients with and
without COU. There was no association between
COU and acute rejections in the ﬁrst year.
Transplant patients report pain symptoms fre-
quently, 43% reported it during the ﬁrst year in
our study. Transplant recipients’ pain issues seem
to be inadequately addressed; in our study, only
about half of the patients reporting pain were get-
ting treated. It is plausible that many patients did
not have pain severe enough to request prescrip-
tion analgesics. The tendency to prescribe opioids
and avoiding NSAIDs seems common in many
transplant centers in the USA and would stand out
in contrast to the analgesic use pattern reported in
Masajtis-Zagajewska’s study (13).
We were interested to ﬁnd the eﬀect of pre-
transplant opioid use on future opioid use, given
the notion that quality of life improves after trans-
plantation and pain problems could resolve in
some cases. Of the 105 pre-transplant opioid users,
only 40 continued to be on chronic opioids after
transplant. On the other hand, one-third of the
post-transplant COUs had a history of COU prior
to transplant. Furthermore, we found that a his-
tory of past illicit drug usage, having a psychiatric
diagnosis, the presence of chronic pain, and a posi-
tive smoking history were also associated with the
post-transplant COU during the ﬁrst year. These
suggest that patients with post-transplant COU
share some similarity with regard to certain comor-
bidities such as chronic pain problem and psychiat-
Table 3. Predictors of death/graft failure in first year after kidney
transplant
Variables AHR 95 % CI p
COU after transplantation, yes 0.84 0.39, 1.81 0.66
PRA ≥ 80 3.05 1.59, 6.27 <0.01
COU prior to transplantation, yes 2.35 1.11, 4.96 0.03
Length of initial inpatient stay, days 1.05 1.01, 1.10 0.02
Private health insurance, yes 0.40 0.19, 0.83 0.01
COU, chronic opioid usage.
Table 4. Multivariate analysis: predictor of death in the first year
after kidney transplantation
Variable AHR 95% CI p
COU post-transplantation, yes 0.82 0.55, 1.24 0.35
Diabetes as cause of ESRD, yes 2.59 1.98, 3.39 <0.01
History of alcohol abuse, yes 1.82 1.29, 2.56 <0.01
COU prior to transplantation, yes 1.60 1.07, 2.39 0.02
First transplant, yes 0.49 0.33, 0.74 <0.01
Recipient age, years 1.05 1.04, 1.07 <0.01
Dialysis duration, years 1.11 1.06, 1.16 <0.01
Initial hospitalization, days 1.04 1.01, 1.07 <0.01
COU, chronic opioid usage.
Table 5. Predictor of death-censored graft loss in the first year after
kidney transplantation
Parameter AHR 95% CI p
Continued opioid use, yes 1.39 0.85, 2.71 0.18
Race, African American 1.95 1.32, 2.89 0.001
Private insurance, yes 0.57 0.39, 0.83 0.004
first transplant, yes 0.36 0.24, 0.55 <.001
Recipient age (years) 0.97 0.96, 0.99 <0.001
Initial hospitalization duration (days) 1.04 1.00, 1.09 0.04
smoking, yes 1.64 1.14, 2.36 0.01
eGFR of allograft, mL/min 0.98 0.96, 0.99 <0.001
Acute rejection in first year, yes 1.68 1.12, 2.51 0.01
Fig. 4. Incidence of acute rejection in the ﬁrst year, by chronic
opioid usage status.
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ric history prior to transplant and social behaviors
including substance abuse and smoking habit.
Only two transplant-related variables predicted
COU: Longer initial hospital stay after the surgery
and the use of rATG as an induction agent, poten-
tial markers for more complicated early postopera-
tive course and for high immunological risk among
those patients who subsequently required chronic
opioid usage.
Barrantes et al. (12), using the same study sam-
ple, have shown that chronic opioid use prior to
transplantation was associated with mortality risk
post-kidney transplantation. Reason cited was
higher comorbidity burden in pre-transplant
chronic opioid users. We had expected to see simi-
lar ﬁndings because, as shown in Table 1, preva-
lence of comorbidities and factors implying
complicated postoperative course such as the
length of initial hospital stay and the occurrence of
DGF is higher among the COU group. However,
multivariate analysis showed the post-transplant
COU was not an independent risk factor for death
after adjusting various known risk factors. This
suggests that comorbidity burden is driving the
higher mortality in post-transplant COU group.
We had hypothesized that COU would be a risk
factor for acute rejections, and thus, possibly
death-censored graft loss because medication non-
compliance is reported more frequently among
patients with chronic pain and opioid analgesic use
(15). Our data, once again, failed to show such
link.
Our analysis of hospitalization after transplanta-
tion showed an association between COU and
multiple hospitalizations, but we cannot imply cau-
sality given the design of our study. Most of repeat
admissions in COU group were related to surgical
complications or the need for invasive procedures.
Mostly the opioids were prescribed for pain associ-
ated with these procedures by the physicians. This
suggests that underlying problem was the compli-
cated clinical course rather than opioid usage. Bet-
ter understanding can only be gauged by a
prospective study.
We acknowledge that the ascertainment of opi-
oid use and outcomes through chart review is an
important limitation. Veriﬁcation of chronic opi-
oid use and pain problem in transplant recipients is
best assessed by a prospective study, but such a
study is hard to execute in absence of preliminary
data from a retrospective study like ours. It is pos-
sible that we may not have captured opioid pre-
scriptions provided by physicians outside of our
health system. This would result in underestima-
tion of true prevalence of COU in our analysis.
Our data collection about hospitalizations could
potentially miss the admissions that occurred at
other hospitals. We also cannot report on quality
of life because these data were not recorded in
charts of our institution.
In conclusion, the COU is relatively common
early after kidney transplantation and not associ-
ated with negative impact on patient and kidney
graft survival. Thus, when clinically indicated and
under close monitoring, judicious use of opioid
analgesic should be provided.
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